Clinical Treatment of Refractory Breast Cancer Based on Organoid Drug Sensitivity Results

Launched by TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL · May 26, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on finding better treatment options for women with refractory breast cancer, which means their cancer has not responded well to standard treatments. The study will create tiny organ-like structures from patients' tumors, called organoids, to test how different cancer drugs affect them. This approach aims to help doctors choose more effective, personalized treatment plans for each patient based on their specific cancer characteristics.

To be eligible for this trial, participants must be women aged 18 to 75 with confirmed breast cancer. They should either have cancer that is operable but has come back during treatment or have non-operable cancer that has changed treatment plans twice in the last six months. Participants will need to provide a small tissue sample for testing and should expect to cooperate with follow-up assessments. This study is currently not yet recruiting, but it hopes to improve treatment options and outcomes for women facing this challenging condition.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Female, aged ≥ 18 years and ≤ 75 years old;
• • 2. Breast cancer confirmed by histology or cytology;
• • 3. One of the following two conditions shall be met: a) Operable breast cancer: Recurrent progression during adjuvant therapy; or the time from initial treatment to the onset of disease progression is less than or equal to 2 years; b) Non-operable breast cancer: patients who have changed two line treatment plans within 6 months;
• • 4. Being able to obtain sufficient fresh tissue specimens for organoid establishment through puncture;
• • 5. Expected survival time ≥ 3 months;
• • 6. The patient voluntarily joined this study and signed an informed consent form (ICF), with good compliance and cooperation in follow-up.
• Exclusion Criteria:
• • 1. Pregnant and lactating women;
• • 2. Patients who have clinically significant (i.e. active) heart disease (such as congestive heart failure, symptomatic coronary artery disease, arrhythmia, etc.) or myocardial infarction within the past 12 months;
• • 3. Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders;
• • 4. The researchers believe that patients are not suitable for inclusion.